KPTI Stock Climbs Following $150 Million USD Royalty Agreement

KPTI Stock

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has announced that it is entering a royalty agreement with HealthCare Royalty Partners, boosting KPTI stock.

Karyopharm, a Massachusettes-based pharmaceutical firm, will receive an initial $75 million USD by the end of this month for HCR, and an additional $75 million USD  once certain regulatory and commercial milestones have been reached. In return, HCR will receive a tiered royalty in the mid-single digits based on worldwide net revenues of Xpovio and any other future products. Xpovio is a product currently being developed by Kyropharm, which can be used to treat patients with ...

Read The Full Article On MicroSmallCap.com

Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.

All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.